ARTSCAN III: A Randomized Phase III Study Comparing Chemoradiotherapy With Cisplatin Versus Cetuximab in Patients With Locoregionally Advanced Head and Neck Squamous Cell Cancer.

ABSTRACT:

Purpose

We performed an open-label randomized controlled phase III study comparing treatment outcome and toxicity between radiotherapy (RT) with concomitant cisplatin versus concomitant cetuximab in patients with locoregionally advanced head and neck squamous cell carcinoma (HNSCC; stage III-IV according to the Union for International Cancer Control TNM classification, 7th edition).

Materials and methods

Eligible patients were randomly assigned 1:1 to receive either intravenous cetuximab 400 mg/m² 1 week before start of RT followed by 250 mg/m²/wk, or weekly intravenous cisplatin 40 mg/m², during RT. RT was conventionally fractionated. Patients with T3-T4 tumors underwent a second random assignment 1:1 between standard RT dose 68.0 Gy to the

SUBMITTER: Gebre-Medhin M 

PROVIDER: S-EPMC7771720 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature